Skip to main content
. Author manuscript; available in PMC: 2014 Mar 15.
Published in final edited form as: Clin Cancer Res. 2013 Jan 28;19(6):1577–1586. doi: 10.1158/1078-0432.CCR-12-2321

Figure 3.

Figure 3

Validation of the 18-hub-gene signature in six independent data sets. (A) Lung ADC patients. (B) Stage I Lung ADC patients. (C) Lung SCC patients. The high- and low-risk groups were defined based on the 18-hub-gene signature which was derived from the Consortium data. The median of the estimated risk scores was used as the cut off to partition the patients into high-risk and low-risk groups. Dashed Grey and solid black lines indicate predicted high- and low-risk groups. Grey and black filled circles represent censored samples. Hazard ratio (HR) compares the overall survival of the high-risk group and the low-risk group. P values were obtained by the log-rank test. The patients with chemotherapy were excluded from the validation sets.